U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 1 to 20 of 633

1.
OpenPVSignal Knowledge Graph: Pharmacovigilance Signal Reports in a Computationally Exploitable FAIR Representation
Achilleas Chytas, George Gavriilides, Anargyros Kapetanakis, Alix de Langlais, Marie-Christine Jaulent, Pantelis Natsiavas
Drug Saf. 2025; 48(4): 425–436. Published online 2025 Feb 8. doi: 10.1007/s40264-024-01503-8
PMCID:
PMC11903642
ArticlePDF–2.0M
2.
Empowering African Expertise: Enhancing Safety Data Integration and Signal Detection for COVID-19 Vaccines Through the African Union Smart Safety Surveillance Joint Signal Management Group
Victoria Prudence Nambasa, Hannah May Gunter, Modupe Bamidele Adeyemo, Neetesh Yanish Bhawaneedin, Marc Blockman, George Tsey Sabblah, John Owusu Gyapong, Eric Muriithi Guantai, Tamrat Abebe, Workeabeba Abebe, Henry Jeremy Lawson, Mercedes Chawada Leburu, Abdullahi Mohammed, Kwame Amponsa-Achiano, Mafora Florah Matlala, Uchenna Geraldine Elemuwa, Hudu Mogtari, Alexander Kwadwo Nyarko, Marione Schönfeldt, Mercy Kamupira, Kerrigan McCarthy, Yohannes Lakew Tefera, Asnakech Alemu, Kabir Mawashi Yusuf, Obi Emelife, Ladji Sidibe, Kudakwashe Dandajena, Kenneth Onu, Mojisola Christianah Adeyeye, Delese Mimi Darko, Heran Gerba, Boitumelo Semete, Fred Siyoi, Aggrey Ambali, Johanna Catharina Meyer
Drug Saf. 2025; 48(3): 233–249. Published online 2025 Jan 22. doi: 10.1007/s40264-024-01493-7
PMCID:
PMC11829835
ArticlePDF–2.4M
3.
Clinical Relatedness and Stability of vigiVec Semantic Vector Representations of Adverse Events and Drugs in Pharmacovigilance
Nils Erlanson, Joana Félix China, Henric Taavola, G. Niklas Norén
Drug Saf. 2025; 48(4): 401–413. Published online 2025 Jan 20. doi: 10.1007/s40264-024-01509-2
PMCID:
PMC11903574
ArticlePDF–2.7M
4.
Performance and Reproducibility of Large Language Models in Named Entity Recognition: Considerations for the Use in Controlled Environments
Jürgen Dietrich, André Hollstein
Drug Saf. 2025; 48(3): 287–303. Published online 2024 Dec 11. doi: 10.1007/s40264-024-01499-1
PMCID:
PMC11829833
ArticlePDF–1.5M
5.
Views on the Development and Use of a New Digital Adverse Drug Event Reporting Platform in Australia: A Qualitative Study
Eyob Alemayehu Gebreyohannes, Christopher Thornton, Myra Thiessen, Sieta T. de Vries, Gretchen Coombs, Indae Hwang, Renly Lim
Drug Saf. 2025; 48(2): 179–190. Published online 2024 Nov 2. doi: 10.1007/s40264-024-01489-3
PMCID:
PMC11785647
ArticlePDF–1.0M
6.
An Integrated Approach for Representing Knowledge on the Potential of Drugs to Cause Acute Kidney Injury
Daniel Fernández-Llaneza, Romy M. P. Vos, Joris E. Lieverse, Helen R. Gosselt, Sandra L. Kane-Gill, Teun van Gelder, Joanna E. Klopotowska, the LEAPfROG Consortium
Drug Saf. 2025; 48(1): 43–58. Published online 2024 Sep 26. doi: 10.1007/s40264-024-01474-w
PMCID:
PMC11711143
ArticlePDF–2.8M
7.
Disproportionality Analysis and Characterisation of Medication Errors in EudraVigilance: Exploring Findings on Sexes and Age Groups
Victor Pera, Jan A. Kors, Erik M. van Mulligen, Marcel de Wilde, Peter R. Rijnbeek, Katia M. C. Verhamme
Drug Saf. 2025; 48(1): 59–74. Published online 2024 Sep 19. doi: 10.1007/s40264-024-01478-6
PMCID:
PMC11711134
ArticlePDF–1.8M
8.
Cardiovascular Safety of Romosozumab Compared to Commonly Used Anti-osteoporosis Medications in Postmenopausal Osteoporosis: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials
Shih-Hao Cheng, William Chu, Wen-Hsiang Chou, Woei-Chyn Chu, Yi-No Kang
Drug Saf. 2025; 48(1): 7–23. Published online 2024 Sep 3. doi: 10.1007/s40264-024-01475-9
PMCID:
PMC11711713
ArticlePDF–1.1M
9.
Short-Term Training, a Useful Approach for Sustainable Pharmacovigilance Knowledge Development in Tanzania, Kenya, Ethiopia and Rwanda
Eugène van Puijenbroek, Abbie Barry, Christabel Khaemba, Lazare Ntirenganya, Tigist Dires Gebreyesus, Adam Fimbo, Omary Minzi, Eyasu Makonnen, Margaret Oluka, Anastasia Guantai, Eleni Aklillu
Drug Saf. 2024; 47(12): 1193–1202. Published online 2024 Aug 20. doi: 10.1007/s40264-024-01469-7
PMCID:
PMC11554700
ArticlePDF–611K
10.
Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System
Michele Fusaroli, Stefano Polizzi, Luca Menestrina, Valentina Giunchi, Luca Pellegrini, Emanuel Raschi, Daniel Weintraub, Maurizio Recanatini, Gastone Castellani, Fabrizio De Ponti, Elisabetta Poluzzi
Drug Saf. 2024; 47(12): 1275–1292. Published online 2024 Aug 15. doi: 10.1007/s40264-024-01471-z
PMCID:
PMC11554833
ArticlePDF–2.0M
11.
Examining the Effect of Missing Data and Unmeasured Confounding on External Comparator Studies: Case Studies and Simulations
Gerd Rippin, Héctor Sanz, Wilhelmina E. Hoogendoorn, Nicolás M. Ballarini, Joan A. Largent, Eleni Demas, Douwe Postmus, Theodor Framke, Lukas M. Aguirre Dávila, Chantal Quinten, Francesco Pignatti
Drug Saf. 2024; 47(12): 1245–1263. Published online 2024 Aug 5. doi: 10.1007/s40264-024-01467-9
PMCID:
PMC11554740
ArticlePDF–1.6M
12.
Correction to: Sharing Adverse Drug Event Reports Between Hospitals and Community Pharmacists to Inform Re-dispensing: An Analysis of Reports and Process Outcomes
Amber Cragg, Serena S. Small, Erica Lau, Adrianna Rowe, Anthony Lau, Katherine Butcher, Corinne M. Hohl
Drug Saf. 2024; 47(9): 925–930. Published online 2024 Aug 5. doi: 10.1007/s40264-024-01452-2
Corrects:
Drug Saf. 2023; 46(11): 1161–1172.
PMCID:
PMC11324615
CorrectionPDF–800K
13.
Description and Validation of a Novel AI Tool, LabelComp, for the Identification of Adverse Event Changes in FDA Labeling
George A. Neyarapally, Leihong Wu, Joshua Xu, Esther H. Zhou, Oanh Dang, Joann Lee, Dharmang Mehta, Rochelle D. Vaughn, Ellen Pinnow, Hong Fang
Drug Saf. 2024; 47(12): 1265–1274. Published online 2024 Jul 31. doi: 10.1007/s40264-024-01468-8
PMCID:
PMC11554693
ArticlePDF–1.5M
14.
Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports
Uma Mahadevan, Gweneth Levy, Lianne Gensler, Mira Ali, Ana P. Lacerda, Lani Wegrzyn, Hannah Palac, Tina Bhutani-Jacques, Millie Long, Megan E. B. Clowse, Alexa B. Kimball, Christina Chambers, Anthony R. Scialli
Drug Saf. 2024; 47(10): 1039–1049. Published online 2024 Jul 15. doi: 10.1007/s40264-024-01454-0
PMCID:
PMC11399166
ArticlePDF–810K
15.
Adopting STOPP/START Criteria Version 3 in Clinical Practice: A Q&A Guide for Healthcare Professionals
Carlotta Lunghi, Marco Domenicali, Stefano Vertullo, Emanuel Raschi, Fabrizio De Ponti, Graziano Onder, Elisabetta Poluzzi
Drug Saf. 2024; 47(11): 1061–1074. Published online 2024 Jul 11. doi: 10.1007/s40264-024-01453-1
PMCID:
PMC11485113
ArticlePDF–785K
16.
The STAR Compass to Guide Future Pharmacovigilance Based on a 10-Year Review of the Strengthened EU System
Priya Bahri, Georgy Genov, Peter Arlett, Viola Macolić Šarinić, Evdokia Korakianiti, Alexis Nolte, Martin Huber, Sabine M. J. M. Straus
Drug Saf. 2024; 47(10): 941–956. Published online 2024 Jul 10. doi: 10.1007/s40264-024-01451-3
PMCID:
PMC11399220
ArticlePDF–1.6M
17.
Optimal Significance Levels and Sample Sizes for Signal Detection Methods Based on Non-constant Hazards
Odile Sauzet, Julia Dyck, Victoria Cornelius
Drug Saf. 2024; 47(11): 1149–1156. Published online 2024 Jul 9. doi: 10.1007/s40264-024-01460-2
PMCID:
PMC11485065
ArticlePDF–689K
18.
Enhanced Safety Surveillance of GSK’s Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season
Ignacio Salamanca de la Cueva, Jennifer E. Gerber, Andrew Hastie, Carlos Brotons, Falko Panzer, Jean-Yves Pirçon, Paul Talsma, Tamara Eckermann, Vanja Nikic, Xavier Martinez Gomez, Hannah Alsdurf
Drug Saf. 2024; 47(11): 1137–1148. Published online 2024 Jun 29. doi: 10.1007/s40264-024-01456-y
PMCID:
PMC11485106
ArticlePDF–1.8M
19.
Pharmacovigilance in Pregnancy Studies, Exposures and Outcomes Ascertainment, and Findings from Low- and Middle-Income Countries: A Scoping Review
Jenine Shafi, Maneet K. Virk, Emma Kalk, James G. Carlucci, Audrey Chepkemoi, Caitlin Bernard, Megan S. McHenry, Edwin Were, John Humphrey, Mary-Ann Davies, Ushma C. Mehta, Rena C. Patel
Drug Saf. 2024; 47(10): 957–990. Published online 2024 Jun 21. doi: 10.1007/s40264-024-01445-1
PMCID:
PMC11399196
ArticlePDF–970K
20.
Correction to: Using Social Media as a Source of Real‑World Data for Pharmaceutical Drug Development and Regulatory Decision Making
Didrik Wessel, Nicolai Pogrebnyakov
Drug Saf. 2024; 47(8): 827. Published online 2024 Jun 14. doi: 10.1007/s40264-024-01459-9
Corrects:
Drug Saf. 2024; 47(5): 495–511.
PMCID:
PMC11286681
CorrectionPDF–368K

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Search details

See more...

Recent activity

You are here: NCBI > Literature > PubMed Central (PMC)
Support Center